A systematic review on the clinical studies of Remdesivir for COVID-19 in selected Asian countries

Joseph Mari Baguilod Querequincia*, Erwin Martinez Faller
Pharmacy Department, San Pedro College, Davao, Philippines.

ARTICLE INFO
Received on: 02/07/2021
Accepted on: 25/10/2021
Available Online: 05/02/2022

Key words:
Remdesivir, COVID-19, antiviral, intravenous, clinical studies, Asian countries.

ABSTRACT
The focal purpose of this review article is to provide ample information on the different clinical studies conducted in some countries in the Asian region on the utilization of the antiviral drug, Remdesivir, for coronavirus disease 2019 (COVID-19). COVID-19 is caused by severe acute respiratory syndrome coronavirus 2 and has spread in most countries in 2020. Common symptoms of this disease include fever, cough, fatigue, and diarrhea. Certain medicinal agents are being studied to treat COVID-19. One of these medicinal agents is Remdesivir, which is an antiviral agent that is an adenosine nucleotide, which could impede the viral RNA polymerase enzyme. There were countries in the regions of Asia that conducted clinical studies on the use of Remdesivir as an antiviral therapy for COVID-19 infections. Asian countries such as Japan and South Korea permitted the employment of it as a medicinal agent for COVID-19 disease. In other countries in the region, Remdesivir is on phase 3 clinical trial. Doses of 100–200 mg/kg intravenous route could improve clinical outcomes of patients infected with COVID-19 in clinical trial settings. Thus, Remdesivir is a potential antiviral commodity that can be used to treat COVID-19 infections and opted to be wholly established.

INTRODUCTION
Coronavirus disease 2019 (COVID-19) is a global medical problem that was detected in the last set of months of 2019. Another nomenclature of its cause is severe acute respiratory syndrome coronavirus 2 (SARS-COV-2). Its symptoms include fever, cough, myalgia, fatigue, and in some cases, diarrhea (Dewangan et al., 2020; Ludvigsson, 2020; Nandy et al., 2020; Rokade and Khandagale, 2020; Viner et al., 2020). It was declared a pandemic by the World Health Organization in March 2020. It widely spread across more than 200 countries in 2020. Healthcare workers and different government sectors of different countries are finding ways to manage this disease and to further prevent its transmission (Jain and Barhate, 2020; Musa et al., 2020; Xu et al., 2020). Moreover, a number of vaccines are developed and are currently programmed to be available to the public soon. There are rare antiviral agents that were approved for the treatment of COVID-19 in some countries, such as Remdesivir (GS-5734), an adenosine nucleotide and antiviral agent that inhibits SARS-COV-2 RNA-dependent RNA polymerase. It was recently approved for the treatment of COVID-19 for infected adults and pediatric patients by the US Food and Drug Administration (Beigel et al., 2020; Yadav and Mohite, 2020a). Here in Asia, there are some countries like Japan and Korea that have already approved the use of this antiviral agent against COVID-19 (Patil and Jain, 2020; Reddy Vegivinti et al., 2021; Yadav and Mohite, 2020). This research paper summarizes the findings through a systematic literature review of the different clinical studies in selected countries of Asia for the utilization of Remdesivir against COVID-19.

METHODS
The review was conducted by utilizing journal databases such as BMJ Global Health, ClinicalTrials.gov, Elsevier, Google Scholar, PubMed, and The Lancet. The search strategy was established for articles on each database without limitations on language and recent years (2019–2021) considered. The search keyword parameters include Remdesivir, GS-5734, NCOV-2019, COVID-19, Remdesivir clinical trials, or a combination of two from these keywords. The search started on February 1, 2021.
Appropriate studies or articles were identified using specific criteria as follows: (1) articles that are focused on clinical trials on Remdesivir, (2) articles related to reports of different trials conducted or participated by a country within the Asian region, and (3) studies that analyze clinical outcomes of Remdesivir for COVID-19. Other considered characteristics for screening of these journal articles consist of the study design, intervention, sample size of participants, and, if any, adverse or side effects of the drug (Derouiche, 2020; Kishor et al., 2021; Penedones et al., 2019; Piscoya et al., 2021; Raymond et al., 2020). For the verification of these clinical studies, the author utilized ClinicalTrials.gov as a reference. There was no online review procedure for this study.

RESULTS AND DISCUSSION

After conducting a search on databases according to the criteria, 620 published articles were characterized. Among these, 320 were excluded due to duplication. There were 300 articles that underwent screening, and 240 of them did not meet the specifications of the criteria. Hence, 60 articles were carefully reviewed. In addition to that, eight more articles were excluded since they were out of scope or the clinical trials were conducted in non-Asian countries, another eight were removed due to insufficient details on clinical trials conducted for Remdesivir, and another six were removed due to the limited sternness of the articles. Thus, there were 40 eligible articles and information on clinical trials of Remdesivir for COVID-19 in the Asian region included in this review. This review of the clinical trials was conducted in selected countries in Asia, such as China, Hong Kong, Japan, Singapore, South Korea, and Taiwan. A number of trials involved a 200 mg intravenous initial dose of Remdesivir, which was administered on the first day of treatment following a succeeding 100 mg dose for 4 days or 9 days. There were 2 clinical trials that utilized 100 mg single dose infusion. The initial outcomes for each trial would include clinical improvements in oxygen degree of saturation, body temperature normalization, and decrease in percentage severity using an ordinal scale used by clinicians to assess the clinical status of the clinical trial participants. Adverse events were also noted by the authors,

Figure 1. PRISMA flow diagram of search screening (inclusion and exclusion) on the review.
mortality, and reduction in viral load (Beigel et al., 2020; Bin Cao China-Japan Friendship Hospital, 2021).

In China, in February 2020, a randomized, placebo-controlled, multicenter phase 3 clinical trial was initiated with enrolled patients admitted to the hospital with confirmed COVID-19 infections. These patients were randomly assigned in a particular ratio to receive the administration of intravenous Remdesivir dosed at 200 mg on the first day and 100 mg on the succeeding days up to the 10th day. There were clinical improvements, such as on the oxygen saturation of the patients up to the 28th day (Reddy Vegivinti et al., 2021; Yang et al., 2021).

Ten hospitals in Hubei, China, were involved in a randomized, double-blind, placebo-controlled clinical trial for the use of Remdesivir with a single daily infusion of 100 mg dose. Enrolled patients were also allowed to be given interferons, corticosteroids, and antivirals, Lopinavir/Ritonavir. They found out that the said dose regimen of Remdesivir was tolerated and did not demonstrate significant clinical outcomes in seriously ill patients, but reductions in clinical immunopathology parameters were also noted. They recommended having a higher dose regimen of Remdesivir to enhance antiviral potency. The clinical study was tracked by Hangzhou Tigermed Consulting, a contract research organization (Chou et al., 2020; Wang et al., 2020).

The adaptive COVID-19 treatment trial, initiated in February 2020 up to April 2020, was conducted in 60 trial sites. Asian countries that participated in the said trial were Japan, Singapore, and South Korea. A 200 mg loading dose followed by a 100 mg daily dose up to 10 days was the regimen for Remdesivir. This is a placebo-controlled and randomized trial assigned in a 1:1 ratio. Good clinical outcomes of the antiviral therapy were

Table 1. Different clinical studies on the use of Remdesivir for COVID-19 participated by Asian countries.

<table>
<thead>
<tr>
<th>Participating countries within the Asian region</th>
<th>ClinicalTrials.gov identifier</th>
<th>Year initiated</th>
<th>Clinical trial phase</th>
<th>Therapeutic dosage of Remdesivir with duration of treatment</th>
<th>Initial outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>China</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hong Kong</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Japan</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Singapore</td>
<td>2020-000842-32</td>
<td>2020</td>
<td>3</td>
<td>100 mg intravenous for 9 days</td>
<td>Early discharge of patients (Shih et al., 2020)</td>
</tr>
<tr>
<td>South Korea</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Taiwan</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>China</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hong Kong</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Japan</td>
<td>2020-000841-15</td>
<td>2020</td>
<td>3</td>
<td>100 mg intravenous for 9 days</td>
<td>Oxygen saturation of patients was enhanced and body temperature became normal (McCreary et al., 2020)</td>
</tr>
<tr>
<td>South Korea</td>
<td>NCT-04280705</td>
<td>2020</td>
<td>3</td>
<td>200 mg intravenous (initial dose); 100 mg intravenous for 9 days</td>
<td>Severity of the disease decreased within 7–15 days (McCreary et al., 2020)</td>
</tr>
<tr>
<td>Taiwan</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Japan</td>
<td>NCT-04252664</td>
<td>2020</td>
<td>3</td>
<td>200 mg intravenous (initial dose); 100 mg intravenous for 9 days</td>
<td>Conditions improvement within 28 days (McCreary et al., 2020)</td>
</tr>
<tr>
<td>South Korea</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Singapore</td>
<td>NCT-0429730</td>
<td>2020</td>
<td>3</td>
<td>200 mg intravenous (initial dose); 100 mg intravenous for 4 days</td>
<td>Enhanced oxygen saturation and early discharge of patients (Spinner et al., 2020)</td>
</tr>
<tr>
<td>China</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hong Kong</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Japan</td>
<td>NCT-04292899</td>
<td>2020</td>
<td>3</td>
<td>200 mg intravenous (initial dose); 100 mg intravenous for 9 days</td>
<td>Oxygen saturation of patients was enhanced and body temperature became normal (Goldman et al., 2020)</td>
</tr>
<tr>
<td>Taiwan</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

mg: milligrams.
observed in the 10-day course of Remdesivir. The data also indicated that the antiviral drug prevented the development of a higher stage of severe respiratory disease (Ikonne et al., 2021; Kichloo et al., 2021; Jo et al., 2021).

In India, the process of application of Remdesivir for its compassionate use is already ongoing. There are two Indian pharmaceutical companies pursued for a clinical study waiver from their health authorities (Dawood, 2021; Devi and Rosy, 2021; Jain and Barhate, 2021; Singh et al., 2020).

A solidarity randomized clinical trial having the registration number ISRCTN83971151 was participated by some Asian countries such as India, Indonesia, Iran, Israel, Lebanon, Malaysia, Philippines, Qatar, Saudi Arabia, and Thailand. In March 2020, it underwent recruitment, and the mode of intervention was standard care and doses of Remdesivir for 10 days. Additional treatment agents such as Chloroquine or Hydroxychloroquine, Lopinavir + Ritonavir, and Beta-Interferon were included (Pan et al., 2021; Pimentel et al., 2020).

In the Philippines, Remdesivir was already granted a permit for compassionate use in hospitals. Ages 12 and above can be administered with this antiviral agent in severe cases of infections of COVID-19 (FDA, 2021).

Remdesivir has exhibited efficacy in both in vitro and in vivo models against coronaviruses. Recently, through compassionate utilization, this drug has adjunct evidence for producing some improvement in the clinical condition of COVID-19 patients (Eastman et al., 2020; Grein et al., 2020).

CONCLUSION

There are still limited clinical investigations that would mend provisions for the full utilization of Remdesivir to treat COVID-19, specifically in Asia. Conversely, a number of phase 3 clinical studies have been completed, and mostly trials are ongoing. There were some pertinent data that were not yet being reported. The profile for adverse effects of Remdesivir is yet to be established. Nevertheless, the results on these phase 3 clinical trials initiated and participated by selected countries in the Asian region proved the significant clinical improvements of conditions of the patients with the intravenous administration of Remdesivir. Hence, this antiviral drug has the potential to be one of the standards for treating COVID-19 and remains to be fully established.

ACKNOWLEDGMENTS

The authors would like to acknowledge San Pedro College, Davao City, Philippines, and Centro Escolar University for their support on this endeavor.

CONFLICT OF INTERESTS

The authors declare that they have no conflicts of interest regarding this review article.

FUNDING

None.

ETHICAL APPROVAL

This study does not involve any utilization of test animals or human subjects.

AUTHORS’ CONTRIBUTIONS

The authors made significant contributions to the concept, design, data, interpretation, and revisions of this article. They are eligible to be an author based on the guidelines set by the esteemed International Committee of Medical Journal Editors (ICMJE).

PUBLISHER’S NOTE

This journal remains neutral with regard to jurisdictional claims in published institutional affiliation.

REFERENCES


